- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Academic Institute
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an ant... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in com... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator:
Phone:
NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In ... Read more >
Status: Enrolling
Investigator: Carrie Yuen
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating pa... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual... Read more >
Status: Enrolling
Investigator: Ross Reul
Study Coordinator: Deena Victor
Phone: 713.441.4536
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Milan Sheth
Phone: 713.790.3311
This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone marro... Read more >
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ... Read more >
Status: Open Not Enrolling
Investigator: Lawrence Rice
Study Coordinator: Melissa Whipple
Phone: 713.441.3247
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition. Prospective longitudinal data in large populations are limited. The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospectivel... Read more >